Skip to content
Back to meeting Original
Nurullah İlhan,MD· @drnurullahilhan · X·· 22 hours agoScore70

KRASCENDO

Body

KRAScendo 1: divarasib met its primary PFS endpoint and improved OS vs a sotorasib-dominant control.
OS: 17.7 vs 12.0 mo; HR 0.56.

Is OS now the benchmark for next-generation KRAS G12C inhibitors?

https://www.nejm.org/doi/10.1056/NEJMoa2605703

@FSkoulidis @myESMO @OncoAlert @OncoDaily #ESMO26

7 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: Nurullah İlhan,MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.